Skip to content

Author

Lanxiang Wu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Multimodal analysis identifies a fibroblast subtype enriched in EGFR-mutant NSCLC and its spatial niches

A mutation-specific stromal-tumor-immune regulatory network is revealed and the COL16A1-integrin β1 pathway is established as a rational therapeutic target to enhance the efficacy of osimertinib and pembrolizumab in EGFR -mutant NSCLC.

Xiao Yang, Xiao-Qing Wang, Min Zhang et al. · 0 citations
Review Jul 2026

STING agonists in tumor therapy: structural pharmacology, determinants of productive activation, and barrier-matched therapeutic strategies.

The cyclic GMP-AMP synthase-stimulator of interferon genes pathway is a central innate immune axis that connects cytosolic DNA sensing with type I interferon production, dendritic-cell activation, and downstream T-cell priming. These functions have positioned stimulator of interferon genes (STING) as an attractive ther...

Chenyi Li, Lanxiang Wu · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.